Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K3 | Q8IVH8 | 11/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 3/20 | 0.48 |
| ▸ | GRK2 | P25098 | 2/20 | 0.48 |
| ▸ | GRK5 | P34947 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177430 | 0.82 | MAP3K7 (0.46) | MAP4K3MET | |
| SCHEMBL10176578 | 0.81 | MAP3K7 (0.46) | MAP4K3MET | |
| SCHEMBL10177301 | 0.81 | MAP3K7 (0.46) | MAP4K3MET | |
| SCHEMBL10177429 | 0.81 | FGFR3 (0.47) | MAP4K3MET | |
| SCHEMBL10176117 | 0.80 | MAP3K7 (0.46) | MAP4K3MET | |
| SCHEMBL10145517 | 0.80 | FGFR3 (0.57) | MAP4K3IRAK4METGRK2GRK5 | |
| SCHEMBL10176243 | 0.80 | KDR (0.46) | MET | |
| SCHEMBL10176246 | 0.80 | FGFR3 (0.51) | MAP4K3MET | |
| SCHEMBL10176110 | 0.80 | MET (0.54) | MET | |
| SCHEMBL10176389 | 0.79 | FYN (0.45) | NTRK1METFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | MAP4K3 519/4885ALK 19/4885IRAK4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.